Evaluation of the Dose Proportionality of Two Dose Strengths (1.5 and 3 mg) of Extended-release Paliperidone After a Single Administration to Healthy Men.
Phase of Trial: Phase I
Latest Information Update: 17 May 2011
At a glance
- Drugs Paliperidone (Primary)
- Indications Psychotic disorders
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 10 Jun 2017 Biomarkers information updated
- 29 Jan 2009 Planned patient numbers amended from 60 to 58 as reported by ClinicalTrials.gov.
- 27 Nov 2008 New trial record.